HPAPI及細胞毒性藥製造市場:各原料藥，各製造地點，各藥物類型，各藥理分子類型，各用途，各地區:規模，佔有率，預測，機會分析(2022年～2030年)

本報告提供全球HPAPI及細胞毒性藥製造市場相關調查，市場概要，以及各原料藥，各製造地點，各藥物類型，各藥理分子類型，各用途，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

• 報告的說明
  • 市場定義和範圍
• 摘要整理
  • 市場明細:各原料藥
  • 市場明細:各製造地點
  • 市場明細:各藥物類型
  • 市場明細:各藥理分子類型
  • 市場明細:各用途
  • 市場明細:各地區
• Coherent Opportunity Map(COM)

第3章 市場動態，法規，及趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 法規情境
• PEST分析
• 最近的產品銷售/核准
• 流行病學
• 合併和收購

第4章 全球HPAPI及細胞毒性藥製造市場-COVID-19大流行的影響

第5章 全球HPAPI及細胞毒性藥製造市場:各原料藥，2017年～2030年(10億美元)

• 簡介
• 化學為基礎的HPAPI
• 生物製藥為基礎的HPAPI

第6章 全球HPAPI及細胞毒性藥製造市場:各製造地點，2017年～2030年(10億美元)

• 簡介
• 內製
• 外包

第7章 全球HPAPI及細胞毒性藥製造市場:各藥物類型，2017年～2030年(10億美元)

• 簡介
• 新HPAPI
• 非專利HPAPI

第8章 全球HPAPI及細胞毒性藥製造市場:各藥理分子類型，2017年～2030年(10億美元)

• 簡介
• 低分子
• 生技藥品

第9章 全球HPAPI及細胞毒性藥製造市場:各用途，2017年～2030年(10億美元)

• 簡介
• 腫瘤學
• 呼吸系統
• 眼科疾病
• 其他

第10章 全球HPAPI及細胞毒性藥製造市場:各地區，2017年～2030年(10億美元)

• 簡介
• 北美
• 南美
• 歐洲
• 亞太地區
• 中東
• 非洲

第11章 競爭情形

• 企業簡介
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Lonza Group
  • Corden Pharma International
  • Evonik Industries AG
  • Flamma Group
  • Merck KGaA
  • CARBOGEN AMCIS
  • Catalent, Inc.
  • Piramal Enterprises Ltd.
  • AbbVie Inc.
  • Fareva Group
  • Cerbios-Pharma SA
  • Novasep
  • Ajinomoto Bio-Pharma
  • PCI Pharma Services
  • Sterling Pharma Solutions
  • Heraeus Holding
  • Polpharma Biologics
  • Helsinn Healthcare SA
  • Seqens
  • Cambrex Corporation
• 分析師的見解

第12章 Section

Highly potent active pharmaceutical ingredients (HPAPI) has an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments. Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.

Cytotoxic drugs are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms.

Market Dynamics

Market players are engaged in inorganic activities, such as acquisitions, in order to expand its product portfolio, this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in January 2019, Flamma Group, a life science company, acquired Teva's Chemical Synthesis Center, the 40,000 sq. ft. cGMP facility in Malvern (U.S.). This laboratory and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, and 1 cGMP HPAPI kilo lab suite.

Key players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in December 2019, Cerbios-Pharma SA announced the authorization by Swissmedic of its cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).

Moreover, in December 2019, Piramal Pharma Solutions, a division of Piramal Enterprises ltd., expanded its manufacturing facility in Riverview, Michigan, with an investment of approximately US$ 32 million to develop and manufacture potent and non-potent active pharmaceutical ingredients (API).

Key features of the study:

• This report provides an in-depth analysis of the global HPAPIs and cytotoxic drugs manufacturing market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

• It profiles leading players in the global HPAPIs and cytotoxic drugs manufacturing market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation

• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

• The global HPAPIs and cytotoxic drugs manufacturing market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts

• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HPAPIs and cytotoxic drugs manufacturing market

Detailed Segmentation:

• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin:
  • Chemical-based HPAPIs
  • Biologic-based HPAPIs
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location:
  • In-house Manufacturing
  • Outsourcing
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type:
  • Novel HPAPIs
  • Generic HPAPIs
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule:
  • Small Molecules
  • Biologics
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application:
  • Oncology
  • Respiratory
  • Ophthalmic Disorders
  • Others
• Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Teva Pharmaceutical Industries Ltd.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Pfizer, Inc.
  • Lonza Group
  • CordenPharma International
  • Evonik Industries AG
  • Flamma Group
  • Merck KGaA
  • CARBOGEN AMCIS
  • Catalent, Inc.
  • Piramal Enterprises Ltd.
  • AbbVie Inc.
  • Fareva Group
  • Cerbios-Pharma SA
  • Novasep
  • Ajinomoto Bio-Pharma
  • PCI Pharma Services
  • Sterling Pharma Solutions
  • Heraeus Holding
  • Polpharma Biologics
  • Helsinn Healthcare SA
  • Seqens
  • Cambrex Corporation

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Origin
  • Market Snippet, By Manufacturing Location
  • Market Snippet, By Drug Type
  • Market Snippet, By Type of Pharmacological Molecule
  • Market Snippet, By Application
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Regulatory Scenario
• PEST Analysis
• Recent Product Launch/Approval
• Epidemiology
• Mergers and Acquisitions

4. Global HPAPIs and Cytotoxic Drugs Manufacturing Market - Impact of Coronavirus (Covid-19) Pandemic

• Impact on Supply Chain
• Impact on Research and Development
• Government Initiatives

5. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Chemical-based HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Biologic-based HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

6. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• In-house Manufacturing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Outsourcing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

7. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Novel HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Generic HPAPIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

8. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Small Molecules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

9. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Respiratory
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Ophthalmic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Billion)

10. Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region, 2017 - 2030 (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• U.S.
• Canada
• Latin America
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Origin, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Manufacturing Location, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Type of Pharmacological Molecule, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Application, 2017 - 2030 (US$ Bn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Bn)
• South Africa
• Central Africa
• North Africa

11. Competitive Landscape

• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Pfizer, Inc.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Lonza Group
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Corden Pharma International
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Evonik Industries AG
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Flamma Group
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Merck KGaA
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • CARBOGEN AMCIS
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Catalent, Inc.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Piramal Enterprises Ltd.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • AbbVie Inc.
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Fareva Group
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Cerbios-Pharma SA
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Novasep
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Ajinomoto Bio-Pharma
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • PCI Pharma Services
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Sterling Pharma Solutions
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Heraeus Holding
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Polpharma Biologics
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Helsinn Healthcare SA
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Seqens
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Cambrex Corporation
• Company Overview
• Drug Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
• Analyst Views

12. Section

• References
• Research Methodology
• About us and Sales Contact